FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916208508> ?p ?o ?g. }

• W2916208508 endingPage "255" @default.
• W2916208508 startingPage "247" @default.
• W2916208508 abstract "Purpose of review Poly(ADP-ribose) polymerase (PARP) inhibitors were recently approved for the treatment of patients with BRCA1 or BRCA2 germline pathogenic variants and metastatic breast cancer. PARP inhibitors have also demonstrated activity in early stage breast cancer, and this review discusses completed and ongoing trials of PARP inhibitors in the neoadjuvant and adjuvant setting. Recent findings A recent phase II trial of neoadjuvant talazoparib monotherapy in patients with BRCA1 or BRCA2 germline pathogenic variants and early stage breast cancer demonstrated a pathological complete response in 10/19 (53%) patients. Previous trials of PARP inhibition in early stage breast cancer included the I-SPY-2 and BrighTNess trials, which ultimately failed to show a benefit for adding the PARP inhibitor veliparib to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. Investigators are building on these results by designing novel clinical trials for patients with BRCA1/2-deficient tumors and/or triple-negative breast cancer. Summary The OlympiAD and EMBRACA trials that led to the recent approval of PARP inhibitors for metastatic breast cancer patients with BRCA1/2 germline pathogenic variants are practice changing. Investigators are now working to translate this success into the early breast cancer setting where ongoing trials incorporate new dosing schedules, PARP inhibitor monotherapy, and novel PARP combinations." @default.
• W2916208508 created "2019-03-02" @default.
• W2916208508 creator A5014713051 @default.
• W2916208508 creator A5073597138 @default.
• W2916208508 date "2019-05-01" @default.
• W2916208508 modified "2023-09-23" @default.
• W2916208508 title "Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer" @default.
• W2916208508 cites W1583886228 @default.
• W2916208508 cites W1905741998 @default.
• W2916208508 cites W1993245114 @default.
• W2916208508 cites W2033624169 @default.
• W2916208508 cites W2033816200 @default.
• W2916208508 cites W2062067118 @default.
• W2916208508 cites W2074730941 @default.
• W2916208508 cites W2075894019 @default.
• W2916208508 cites W2086064725 @default.
• W2916208508 cites W2094523134 @default.
• W2916208508 cites W2094929011 @default.
• W2916208508 cites W2095633632 @default.
• W2916208508 cites W2096745115 @default.
• W2916208508 cites W2096843793 @default.
• W2916208508 cites W2098737737 @default.
• W2916208508 cites W2101519297 @default.
• W2916208508 cites W2105265201 @default.
• W2916208508 cites W2111429259 @default.
• W2916208508 cites W2112241575 @default.
• W2916208508 cites W2121415861 @default.
• W2916208508 cites W2123588904 @default.
• W2916208508 cites W2126999423 @default.
• W2916208508 cites W2134539328 @default.
• W2916208508 cites W2142460765 @default.
• W2916208508 cites W2144510519 @default.
• W2916208508 cites W2155244882 @default.
• W2916208508 cites W2160466424 @default.
• W2916208508 cites W2166702788 @default.
• W2916208508 cites W2235405584 @default.
• W2916208508 cites W2235523093 @default.
• W2916208508 cites W2304716045 @default.
• W2916208508 cites W2318905487 @default.
• W2916208508 cites W2345680184 @default.
• W2916208508 cites W2402636472 @default.
• W2916208508 cites W2474664935 @default.
• W2916208508 cites W2519148856 @default.
• W2916208508 cites W2529709253 @default.
• W2916208508 cites W2561042858 @default.
• W2916208508 cites W2584184455 @default.
• W2916208508 cites W2596164112 @default.
• W2916208508 cites W2598264809 @default.
• W2916208508 cites W2621271973 @default.
• W2916208508 cites W2734897937 @default.
• W2916208508 cites W2744945030 @default.
• W2916208508 cites W2753910311 @default.
• W2916208508 cites W2763602017 @default.
• W2916208508 cites W2767593721 @default.
• W2916208508 cites W2773549447 @default.
• W2916208508 cites W2788106879 @default.
• W2916208508 cites W2789481433 @default.
• W2916208508 cites W2801956643 @default.
• W2916208508 cites W2805546308 @default.
• W2916208508 cites W2805734855 @default.
• W2916208508 cites W2805956109 @default.
• W2916208508 cites W2808113406 @default.
• W2916208508 cites W2873526615 @default.
• W2916208508 cites W2883673963 @default.
• W2916208508 cites W2886477543 @default.
• W2916208508 cites W2889669338 @default.
• W2916208508 cites W2889709939 @default.
• W2916208508 cites W2892812402 @default.
• W2916208508 cites W2895846919 @default.
• W2916208508 cites W2897430921 @default.
• W2916208508 cites W2906986535 @default.
• W2916208508 cites W4211006558 @default.
• W2916208508 doi "https://doi.org/10.1097/cco.0000000000000516" @default.
• W2916208508 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30789866" @default.
• W2916208508 hasPublicationYear "2019" @default.
• W2916208508 type Work @default.
• W2916208508 sameAs 2916208508 @default.
• W2916208508 citedByCount "7" @default.
• W2916208508 countsByYear W29162085082019 @default.
• W2916208508 countsByYear W29162085082020 @default.
• W2916208508 countsByYear W29162085082021 @default.
• W2916208508 countsByYear W29162085082023 @default.
• W2916208508 crossrefType "journal-article" @default.
• W2916208508 hasAuthorship W2916208508A5014713051 @default.
• W2916208508 hasAuthorship W2916208508A5073597138 @default.
• W2916208508 hasConcept C104317684 @default.
• W2916208508 hasConcept C121608353 @default.
• W2916208508 hasConcept C126322002 @default.
• W2916208508 hasConcept C143998085 @default.
• W2916208508 hasConcept C182979987 @default.
• W2916208508 hasConcept C2776694085 @default.
• W2916208508 hasConcept C2779138821 @default.
• W2916208508 hasConcept C2780110267 @default.
• W2916208508 hasConcept C2781312401 @default.
• W2916208508 hasConcept C530470458 @default.
• W2916208508 hasConcept C535046627 @default.
• W2916208508 hasConcept C55493867 @default.
• W2916208508 hasConcept C71924100 @default.

• next